WO2004011498A3 - Long lasting natriuretic peptide derivatives - Google Patents

Long lasting natriuretic peptide derivatives Download PDF

Info

Publication number
WO2004011498A3
WO2004011498A3 PCT/CA2003/001097 CA0301097W WO2004011498A3 WO 2004011498 A3 WO2004011498 A3 WO 2004011498A3 CA 0301097 W CA0301097 W CA 0301097W WO 2004011498 A3 WO2004011498 A3 WO 2004011498A3
Authority
WO
WIPO (PCT)
Prior art keywords
long lasting
natriuretic peptide
peptide derivatives
peptide
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2003/001097
Other languages
French (fr)
Other versions
WO2004011498A2 (en
Inventor
Dominique P Bridon
Peter Bakis
Julie Carette
France Leclaire
Roger Leger
Martin Robitaille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Inc
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/471,348 priority Critical patent/US20040266673A1/en
Priority to AU2003246500A priority patent/AU2003246500A1/en
Priority to EP03771007A priority patent/EP1530588A2/en
Priority to JP2004523679A priority patent/JP2006514607A/en
Priority to CA002488348A priority patent/CA2488348A1/en
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Publication of WO2004011498A2 publication Critical patent/WO2004011498A2/en
Publication of WO2004011498A3 publication Critical patent/WO2004011498A3/en
Priority to US11/040,810 priority patent/US20050176641A1/en
Anticipated expiration legal-status Critical
Priority to US11/067,556 priority patent/US7601691B2/en
Priority to US11/923,222 priority patent/US7906482B2/en
Priority to US11/926,843 priority patent/US20080199532A1/en
Priority to US12/253,856 priority patent/US20090275506A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to long lasting natriuretic peptide (NP) derivatives. The NP derivative has a NP peptide and a reactive entity coupled to the NP peptide. The reactive entity is able to covalently bond with a functionality on a blood component. In particular, this invention relates to NP derivatives having an extended in vivo half-life, and method for the treatment of cardio-vascular diseases and disorders such as acute decompensated congestive heart failure (CHF) and chronic CHF.
PCT/CA2003/001097 1999-05-17 2003-07-29 Long lasting natriuretic peptide derivatives Ceased WO2004011498A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/471,348 US20040266673A1 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives
AU2003246500A AU2003246500A1 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives
EP03771007A EP1530588A2 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives
JP2004523679A JP2006514607A (en) 2002-07-31 2003-07-29 Long-lasting sodium excretion increasing peptide derivative
CA002488348A CA2488348A1 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives
US11/040,810 US20050176641A1 (en) 2000-05-17 2005-01-21 Long lasting natriuretic peptide derivatives
US11/067,556 US7601691B2 (en) 1999-05-17 2005-02-25 Anti-obesity agents
US11/923,222 US7906482B2 (en) 1999-05-17 2007-10-24 Anti-obesity agents
US11/926,843 US20080199532A1 (en) 1999-05-17 2007-10-29 Long Lasting Natriuretic Peptide Derivatives
US12/253,856 US20090275506A1 (en) 2000-05-17 2008-10-17 Long lasting natriuretic peptide derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40041302P 2002-07-31 2002-07-31
US40019902P 2002-07-31 2002-07-31
US60/400,413 2002-07-31
US60/400,199 2002-07-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/471,348 A-371-Of-International US20040266673A1 (en) 1999-05-17 2003-07-29 Long lasting natriuretic peptide derivatives
US11/040,810 Continuation US20050176641A1 (en) 1999-05-17 2005-01-21 Long lasting natriuretic peptide derivatives

Publications (2)

Publication Number Publication Date
WO2004011498A2 WO2004011498A2 (en) 2004-02-05
WO2004011498A3 true WO2004011498A3 (en) 2004-06-24

Family

ID=31191354

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001097 Ceased WO2004011498A2 (en) 1999-05-17 2003-07-29 Long lasting natriuretic peptide derivatives

Country Status (5)

Country Link
EP (1) EP1530588A2 (en)
JP (2) JP2006514607A (en)
AU (1) AU2003246500A1 (en)
CA (1) CA2488348A1 (en)
WO (1) WO2004011498A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7662773B2 (en) 2002-11-26 2010-02-16 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US8071560B2 (en) 2004-02-17 2011-12-06 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US8148114B2 (en) 2004-02-17 2012-04-03 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US8623835B2 (en) 2002-09-06 2014-01-07 University Of South Florida Materials and methods for treatment of respiratory allergic diseases
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
DK1360202T3 (en) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Prolonged glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal disorders and disorders
PL1759001T3 (en) 2004-04-21 2011-09-30 Alexion Pharma Inc Bone delivery conjugates and method of using same to target proteins to bone
WO2006005140A2 (en) 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
WO2006094764A1 (en) * 2005-03-07 2006-09-14 Mondobiotech Licensing Out Ag Formulation for aviptadil
WO2006108686A2 (en) * 2005-04-14 2006-10-19 Aic Bnp agonists
WO2007041645A2 (en) * 2005-10-03 2007-04-12 Scios Inc. Oxidized human bnp
JP5010913B2 (en) * 2006-12-31 2012-08-29 寿子 小出 Tissue regeneration preparation containing atrial diuretic hormone family molecule as active substance, tissue regeneration method using the preparation, hair growth, hair growth, hair restorer and skin tissue repair improving agent containing atrial diuretic hormone family molecule as active substance Hair growth, hair thickening, hair growth promoting method and skin tissue repair improving method using the preparation
KR20080098216A (en) * 2007-05-04 2008-11-07 한미약품 주식회사 Sodium excretion peptide drug conjugate using a carrier substance
US20100310561A1 (en) * 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
AU2008274845A1 (en) 2007-07-06 2009-01-15 Theratechnologies Inc. Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-MSH) and atrial natriuretic protein (ANP) and uses in hypertension and acute kidney injury
WO2012013597A1 (en) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Substances and the use thereof for influencing natriuretic peptide receptors
DE102010032482A1 (en) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen New receptor agonist having renin-suppressing activity, antihypertrophic activity and influence of second messenger cyclic guanosine monophosphate during vasodilation, natriuresis and diuresis, useful to treat e.g. nephrotic syndrome
JP6055779B2 (en) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド Composition comprising natriuretic peptide and method of use thereof
JP5850953B2 (en) * 2011-02-23 2016-02-03 マデライン ファーマシューティカルズ ピーティーワイ リミテッドＭａｄｅｌｅｉｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｐｔｙ Ｌｔｄ Therapeutic methods for treating congestive heart failure
CN102286092B (en) 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 Solid-phase synthesis method of liraglutide
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (en) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド Treatment of seizures with recombinant alkaline phosphatase
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
TW201708247A (en) * 2015-05-29 2017-03-01 Igisu Co Ltd Cyclic peptide and drug, external preparation and cosmetic containing the same
JP6993961B2 (en) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド Production of alkaline phosphatase
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFICIENT POSOLOGICAL REGIMES FOR NON-SPECIFIC TISSUE ALKALINE ENZYME PHOSPHATASE REPLACEMENT HYPOPHOSPHATASE (TNSALP) THERAPY
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20180125979A (en) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 Treatment of muscle weakness with alkaline phosphatase
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (en) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat bronchomalacia
KR20190129058A (en) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 How to treat hypophosphatase (HPP) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN120435308A (en) 2022-10-21 2025-08-05 伊莱利利公司 Long-acting natriuretic peptide and its use
CN116284329B (en) * 2023-04-28 2023-12-08 成都奥达生物科技有限公司 Long-acting natriuretic peptide compound
CN121717878A (en) * 2024-12-02 2026-03-24 中山大学 Ultra-long-acting polypeptide for NPR-B targeting and application thereof in skeletal system diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT45082A (en) * 1985-11-05 1988-05-30 Biotechnology Res Ass Process for preparing atrial natriuretic peptides
JP3042782B2 (en) * 1985-11-05 2000-05-22 サイオス インコーポレイテッド Atrial natriuretic peptide-enhancing compound
GR1001018B (en) * 1989-05-24 1993-03-31 Abbott Lab Method for preparing precursor peptic derivatives
EP1171582A2 (en) * 1999-05-17 2002-01-16 Conjuchem, Inc. Long lasting anti-angiogenic peptides
EP1235618A2 (en) * 1999-09-07 2002-09-04 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEGER ROGER ET AL: "Synthesis and in vitro analysis of atrial natriuretic peptide-albumin conjugates.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 20, 20 October 2003 (2003-10-20), pages 3571 - 3575, XP001156881, ISSN: 0960-894X *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623835B2 (en) 2002-09-06 2014-01-07 University Of South Florida Materials and methods for treatment of respiratory allergic diseases
US7662773B2 (en) 2002-11-26 2010-02-16 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US8071560B2 (en) 2004-02-17 2011-12-06 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US8148114B2 (en) 2004-02-17 2012-04-03 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9884124B2 (en) 2012-05-17 2018-02-06 Extend Biosciences, Inc. Carriers for improved drug delivery
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9289507B2 (en) 2012-05-17 2016-03-22 Extend Biosciences, Inc. Carriers for improved drug delivery
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US10406202B2 (en) 2014-10-22 2019-09-10 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US10420819B2 (en) 2014-10-22 2019-09-24 Extend Biosciences, Inc. Insulin vitamin D conjugates
US10702574B2 (en) 2014-10-22 2020-07-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US11116816B2 (en) 2014-10-22 2021-09-14 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US12076366B2 (en) 2014-10-22 2024-09-03 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Also Published As

Publication number Publication date
JP2010047614A (en) 2010-03-04
EP1530588A2 (en) 2005-05-18
CA2488348A1 (en) 2004-02-05
JP2006514607A (en) 2006-05-11
WO2004011498A2 (en) 2004-02-05
AU2003246500A1 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
WO2004066805A3 (en) In vivo device for improving diastolic ventricular function
WO2009067639A3 (en) Variants of c-type natriuretic peptide
WO2000069900A3 (en) Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2004020410A3 (en) Dihydropyridinone derivatives as hne inhibitors
EP1408038A3 (en) Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
WO2003092541A3 (en) Hardenable orthopaedic supports
AU2002313743A1 (en) Treatment of congestive heart failure and autonomic cardiovascular drive disorders
WO2001037850A3 (en) Use of a milk protein hydrolysate in the treatment of diabetes
AU2003240833A1 (en) Low profile inlet for an implantable blood pump
WO2002060389A3 (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
AU2001251514A1 (en) Method for detecting cheyne-stokes respiration in patients with congestive heart failure
WO2006057920A3 (en) Devices, systems, and methods for energy assisted arterio-venous fistula creation
WO2000074666A3 (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
WO2004021925A3 (en) Vascular prosthesis, especially for replacing the ascending aorta
WO2002024108A3 (en) A device and an introducer for providing a supplemental flow of blood
WO2004083369A3 (en) Tissue binding composition
WO2001091826A3 (en) Cannula assembly for medical applications and method of manufacture
AU2003268218A1 (en) Flexible composite guidewire for intravascular catheter
AU2003257162A1 (en) Catheter for cardiac injection
WO2001003684A3 (en) Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
AU2003257187A1 (en) Dialysis catheters with optimized user-friendly connections
AU2003278362A1 (en) Method of forward error correction
AU2003214210A1 (en) Treatment of congestive heart failure with natriuretic peptide and a diuretic
AU2003211107A1 (en) Method for curing cyanoacrylate adhesives
WO2005042063A8 (en) Extra-aortic patch

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10471348

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2488348

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003246500

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003771007

Country of ref document: EP

Ref document number: 2004523679

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003771007

Country of ref document: EP